Lyn is also involved in nilotinib resistance to cancer treatments [25,26], Zardan et al. suggested Lyn as a critical regulator of androgen receptor (AR) expression and activity, particularly in androgen-deprived conditions [14]. Here, LYN is linked to cancer.